Genetically engineered mesenchymal stem cells for cell and gene therapy

Yunjoon Jung, Jan Nolta

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Stem cells have enormous potential for regenerative medicine to treat fatal diseases and injuries that cannot otherwise be healed. In particular, adult stem cell-based therapies have been studied for several decades. Mesenchymal stem cells/marrow stromal cells (MSCs) have shown safety and therapeutic efficacy in preclinical models of various diseases such as cardiovascular disease, cancer, bone defects, renal failure, and neurodegenerative disorders. In spite of the great potential, several factors including low survival rate, low efficiency of MSC homing to injured sites, and poor levels of engraftment and retention have been major technical challenges to be overcome before MSC-based therapy can be applied to clinical applications in a consistently therapeutic manner. Genetically modified MSCs can be one option to overcome some of these problems and to deliver therapeutic agents. MSCs are powerful delivery vehicles and potent protein synthesis factories, and therefore the use of gene-modified MSCs to provide growth factors and other signals to improve the repair of damaged or diseased tissues holds much promise. Here we review the basic biology of human MSCs and the current status of preclinical and clinical trials using genetically engineered MSCs.

Original languageEnglish (US)
Title of host publicationMesenchymal Stem Cell Therapy
PublisherHumana Press Inc.
Pages321-354
Number of pages34
ISBN (Electronic)9781627032001
ISBN (Print)9781627031998
DOIs
StatePublished - Jan 1 2013

Fingerprint

Gene therapy
Stromal Cells
Cell- and Tissue-Based Therapy
Stem cells
Mesenchymal Stromal Cells
Genetic Therapy
Bone Marrow
Industrial plants
Intercellular Signaling Peptides and Proteins
Bone
Repair
Genes
Cells
Tissue
Defects
Bone Neoplasms
Adult Stem Cells
Regenerative Medicine
Proteins
Neurodegenerative Diseases

Keywords

  • Bone disease
  • Cancer
  • Cellular therapy
  • Clinical trials
  • Gene therapy
  • Growth factor production
  • Mesenchymal stem cells
  • Neurodegenerative disorders
  • Preclinical models
  • Regenerative medicine
  • Renal disease
  • Revascularization

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Jung, Y., & Nolta, J. (2013). Genetically engineered mesenchymal stem cells for cell and gene therapy. In Mesenchymal Stem Cell Therapy (pp. 321-354). Humana Press Inc.. https://doi.org/10.1007/978-1-62703-200-1_15

Genetically engineered mesenchymal stem cells for cell and gene therapy. / Jung, Yunjoon; Nolta, Jan.

Mesenchymal Stem Cell Therapy. Humana Press Inc., 2013. p. 321-354.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jung, Yunjoon ; Nolta, Jan. / Genetically engineered mesenchymal stem cells for cell and gene therapy. Mesenchymal Stem Cell Therapy. Humana Press Inc., 2013. pp. 321-354
@inbook{ee09d04930eb47dcbf4b1f59e69acd50,
title = "Genetically engineered mesenchymal stem cells for cell and gene therapy",
abstract = "Stem cells have enormous potential for regenerative medicine to treat fatal diseases and injuries that cannot otherwise be healed. In particular, adult stem cell-based therapies have been studied for several decades. Mesenchymal stem cells/marrow stromal cells (MSCs) have shown safety and therapeutic efficacy in preclinical models of various diseases such as cardiovascular disease, cancer, bone defects, renal failure, and neurodegenerative disorders. In spite of the great potential, several factors including low survival rate, low efficiency of MSC homing to injured sites, and poor levels of engraftment and retention have been major technical challenges to be overcome before MSC-based therapy can be applied to clinical applications in a consistently therapeutic manner. Genetically modified MSCs can be one option to overcome some of these problems and to deliver therapeutic agents. MSCs are powerful delivery vehicles and potent protein synthesis factories, and therefore the use of gene-modified MSCs to provide growth factors and other signals to improve the repair of damaged or diseased tissues holds much promise. Here we review the basic biology of human MSCs and the current status of preclinical and clinical trials using genetically engineered MSCs.",
keywords = "Bone disease, Cancer, Cellular therapy, Clinical trials, Gene therapy, Growth factor production, Mesenchymal stem cells, Neurodegenerative disorders, Preclinical models, Regenerative medicine, Renal disease, Revascularization",
author = "Yunjoon Jung and Jan Nolta",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-62703-200-1_15",
language = "English (US)",
isbn = "9781627031998",
pages = "321--354",
booktitle = "Mesenchymal Stem Cell Therapy",
publisher = "Humana Press Inc.",

}

TY - CHAP

T1 - Genetically engineered mesenchymal stem cells for cell and gene therapy

AU - Jung, Yunjoon

AU - Nolta, Jan

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Stem cells have enormous potential for regenerative medicine to treat fatal diseases and injuries that cannot otherwise be healed. In particular, adult stem cell-based therapies have been studied for several decades. Mesenchymal stem cells/marrow stromal cells (MSCs) have shown safety and therapeutic efficacy in preclinical models of various diseases such as cardiovascular disease, cancer, bone defects, renal failure, and neurodegenerative disorders. In spite of the great potential, several factors including low survival rate, low efficiency of MSC homing to injured sites, and poor levels of engraftment and retention have been major technical challenges to be overcome before MSC-based therapy can be applied to clinical applications in a consistently therapeutic manner. Genetically modified MSCs can be one option to overcome some of these problems and to deliver therapeutic agents. MSCs are powerful delivery vehicles and potent protein synthesis factories, and therefore the use of gene-modified MSCs to provide growth factors and other signals to improve the repair of damaged or diseased tissues holds much promise. Here we review the basic biology of human MSCs and the current status of preclinical and clinical trials using genetically engineered MSCs.

AB - Stem cells have enormous potential for regenerative medicine to treat fatal diseases and injuries that cannot otherwise be healed. In particular, adult stem cell-based therapies have been studied for several decades. Mesenchymal stem cells/marrow stromal cells (MSCs) have shown safety and therapeutic efficacy in preclinical models of various diseases such as cardiovascular disease, cancer, bone defects, renal failure, and neurodegenerative disorders. In spite of the great potential, several factors including low survival rate, low efficiency of MSC homing to injured sites, and poor levels of engraftment and retention have been major technical challenges to be overcome before MSC-based therapy can be applied to clinical applications in a consistently therapeutic manner. Genetically modified MSCs can be one option to overcome some of these problems and to deliver therapeutic agents. MSCs are powerful delivery vehicles and potent protein synthesis factories, and therefore the use of gene-modified MSCs to provide growth factors and other signals to improve the repair of damaged or diseased tissues holds much promise. Here we review the basic biology of human MSCs and the current status of preclinical and clinical trials using genetically engineered MSCs.

KW - Bone disease

KW - Cancer

KW - Cellular therapy

KW - Clinical trials

KW - Gene therapy

KW - Growth factor production

KW - Mesenchymal stem cells

KW - Neurodegenerative disorders

KW - Preclinical models

KW - Regenerative medicine

KW - Renal disease

KW - Revascularization

UR - http://www.scopus.com/inward/record.url?scp=85029444279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029444279&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-200-1_15

DO - 10.1007/978-1-62703-200-1_15

M3 - Chapter

AN - SCOPUS:85029444279

SN - 9781627031998

SP - 321

EP - 354

BT - Mesenchymal Stem Cell Therapy

PB - Humana Press Inc.

ER -